Navigation Links
ViroPharma Launches 'Swell,' an Original Documentary Chronicling the Lives of People Living with Hereditary Angioedema
Date:5/26/2011

EXTON, Pa., May 26, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the launch of the documentary Swell, a twenty-five minute film that allows families dealing with the rare genetic swelling disease, hereditary angioedema (HAE), to share the challenges and triumphs of living with a chronic disorder. Swell also explores the perspective of physicians that manage HAE, often times through many generations of the same family. The film can be viewed in its entirety at www.swellmovie.com.

The film website also contains important resources for anyone touched by the disease, or those who want to better understand the everyday life of these extraordinary people. The site will be updated with new video footage and information on a regular basis.

"Over the past few years, everyone at ViroPharma has been touched, humbled and motivated by people living with this rare, devastating condition," stated Kristina Broadbelt, ViroPharma's associate director of global public relations and advocacy. "Those interactions had so much impact, we thought it important to find a way to share the stories of strength, courage and perseverance with as large an audience as possible," continued Broadbelt.

ViroPharma tapped award winning documentary film-maker, Marc Brodzik, and his production company Woodshop Films (www.woodshopfilms.com) of Philadelphia, PA to produce, shoot and direct the film. Unlike the traditional patient video format, the film was shot with the Cinema verite approach, combining naturalistic techniques with low fi stylized cinematic devices of editing and camerawork, staged set-ups, and the use of the camera to help uncover the true nature of its subjects.

"I was very excited to participate in this important project," said Dr. David Hurewitz, an allergist/immunologist at the Allergy Clinic of Tulsa in Tulsa, Okla. "Raising awareness of rare disorders is critically important, and may help in the diagnosis of the disease. In addition, a film like this can help assure those dealing with such a rare condition that they are not alone."

This film is one in a series of programs that demonstrates ViroPharma's commitment to raising awareness of hereditary angioedema and to supporting the rare disease community. All of these programs – including Swell -- can be accessed at HAEandME.com.

About Hereditary Angioedema

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options.  Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. 

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's website, http://www.viropharma.com/. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Initiates Phase 2 Study of VP 20621 for Prevention of Recurrence of Clostridium difficile Infection (CDI)
2. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
3. ViroPharma and Halozyme Announce Collaboration for Combination of Recombinant Human Hyaluronidase Enzyme (rHuPH20) Technology with C1 Esterase Inhibitor
4. ViroPharma to Participate In Three May Healthcare Investor Conferences
5. ViroPharma to Release 2011 First Quarter Financial Results On April 28, 2011
6. ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR)
7. ViroPharma Launches HAE and Me, A New Online Community to Unite People Living With Hereditary Angioedema
8. ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
9. ViroPharma Announces Securities Repurchase Program
10. ViroPharma to Participate in Two March Healthcare Conferences
11. ViroPharma to Release 2010 Fourth Quarter and Full Year Financial Results on February 24, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... , May 24, 2016 ... doble terapia del mundo, introduce catéteres para la ... OrbusNeich, una compañía global especializada en el ... ha expandido su cartera incluyendo productos para tratar ... y Scoreflex™ PTA son los dispositivos de primera ...
(Date:5/24/2016)... May 24, 2016 Open Access ... Clinical Neurophysiology  Elsevier , a world-leading ... services, today announced the launch of Clinical ... journal that focuses on clinical practice issues in clinical ... clinical series, normal values and didactic reviews. It is ...
(Date:5/24/2016)... , May 24, 2016 Een ... verbindt, zodat zij collectief patiënten kunnen behandelen, hun kennis ... het idee achter de nieuwe en revolutionaire MDLinking App, ... de Nederlandse vaatchirurg dr. Hans Flu en oncologisch chirurg ... die inmiddels beschikbaar is, wordt op dinsdag 24 mei ...
Breaking Medicine Technology:
(Date:5/24/2016)... New York, NY (PRWEB) , ... May 24, ... ... of rehabilitative treatment for physical disease or injury that focuses on repairing the ... surgery. , With an emphasis on functional restoration, NYDNRehab began providing treatments ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... egg freezing, today announced the official relaunch of its community and education hub ... frozen eggs. Eggsurance's mission is to create a safe and welcoming place for ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... 2016 increased by 9.3 million people, or 10% over last year, according to ... people covered under group policies was comparatively stable, with a slight decrease in ...
(Date:5/24/2016)... ... ... launched the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and raise ... do not have access to a toilet, even when they’re on their periods. , WaterAid ... (sometimes hilarious) results help shine a light on the awkwardness that women face while menstruating, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Harvard Health Publications, ... relationship that will deliver a new series of Q&A videos to clinicians and ... knowledge and expertise of Harvard Medical School faculty into brief videos that clinicians ...
Breaking Medicine News(10 mins):